Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent Exherin (ADH 1) administered once daily for 5 consecutive days by intravenous infusion in subjects with N-cadherin expressing, incurable, solid tumours (Adherex protocol number AHX 01 003)

Trial Profile

Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent Exherin (ADH 1) administered once daily for 5 consecutive days by intravenous infusion in subjects with N-cadherin expressing, incurable, solid tumours (Adherex protocol number AHX 01 003)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2006

At a glance

  • Drugs ADH 1 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top